Burney Co. Cuts Stock Position in Unum Group (NYSE:UNM)

Burney Co. trimmed its position in Unum Group (NYSE:UNM - Free Report) by 12.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 105,685 shares of the financial services provider's stock after selling 14,639 shares during the period. Burney Co. owned 0.06% of Unum Group worth $7,718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in shares of Unum Group in the third quarter worth about $31,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Unum Group in the third quarter worth about $37,000. V Square Quantitative Management LLC grew its holdings in Unum Group by 38.2% during the third quarter. V Square Quantitative Management LLC now owns 702 shares of the financial services provider's stock worth $42,000 after acquiring an additional 194 shares during the period. William B. Walkup & Associates Inc. purchased a new position in Unum Group during the second quarter valued at approximately $44,000. Finally, Quarry LP raised its position in Unum Group by 4,794.7% during the third quarter. Quarry LP now owns 930 shares of the financial services provider's stock valued at $55,000 after acquiring an additional 911 shares in the last quarter. Institutional investors and hedge funds own 86.57% of the company's stock.

Unum Group Price Performance

Shares of NYSE UNM traded up $0.28 during midday trading on Wednesday, hitting $73.26. The stock had a trading volume of 1,249,141 shares, compared to its average volume of 1,221,644. The company has a quick ratio of 0.28, a current ratio of 0.28 and a debt-to-equity ratio of 0.32. The stock has a 50 day simple moving average of $73.32 and a 200-day simple moving average of $62.48. The company has a market capitalization of $13.38 billion, a PE ratio of 7.93, a P/E/G ratio of 1.06 and a beta of 0.81. Unum Group has a 1 year low of $44.83 and a 1 year high of $77.63.

Unum Group (NYSE:UNM - Get Free Report) last announced its earnings results on Tuesday, October 29th. The financial services provider reported $2.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.10 by $0.03. The company had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.26 billion. Unum Group had a net margin of 13.76% and a return on equity of 15.21%. The firm's quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.94 EPS. On average, sell-side analysts expect that Unum Group will post 8.54 EPS for the current fiscal year.

Unum Group Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, January 24th. This represents a $1.68 annualized dividend and a dividend yield of 2.29%. Unum Group's dividend payout ratio is presently 18.18%.

Analyst Upgrades and Downgrades

UNM has been the topic of several recent research reports. Piper Sandler upped their price objective on Unum Group from $74.00 to $82.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th. UBS Group raised shares of Unum Group to a "hold" rating in a report on Wednesday, October 9th. Wells Fargo & Company lifted their price objective on shares of Unum Group from $74.00 to $81.00 and gave the company an "overweight" rating in a report on Tuesday. Morgan Stanley upped their price objective on shares of Unum Group from $62.00 to $64.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 30th. Finally, Truist Financial raised their target price on Unum Group from $70.00 to $75.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $75.45.

Insider Activity

In related news, EVP Elizabeth Claire Ahmed sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $64.16, for a total value of $320,800.00. Following the transaction, the executive vice president now directly owns 58,741 shares in the company, valued at approximately $3,768,822.56. This represents a 7.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Walter Lynn Rice, Jr. sold 1,500 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $69.56, for a total value of $104,340.00. Following the sale, the chief accounting officer now directly owns 8,361 shares of the company's stock, valued at approximately $581,591.16. This trade represents a 15.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 107,914 shares of company stock valued at $7,998,745. 0.93% of the stock is currently owned by insiders.

Unum Group Profile

Unum Group, together with its subsidiaries, provides financial protection benefit solutions primarily in the United States, the United Kingdom, Poland, and internationally. It operates through Unum US, Unum International, Colonial Life, and Closed Block segment. The company offers group long-term and short-term disability, group life, and accidental death and dismemberment products; supplemental and voluntary products, such as individual disability, voluntary benefits, and dental and vision products; and accident, sickness, disability, life, and cancer and critical illness products.